# Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer

> **NCT00376623** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 96 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** BI 2536

## Key facts

- **NCT ID:** NCT00376623
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07-25
- **Primary completion:** 2008-04-01
- **Final completion:** 2008-04-01
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2022-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00376623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00376623, "Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00376623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*